XML 37 R23.htm IDEA: XBRL DOCUMENT
v3.22.0.1

STOCK-BASED COMPENSATION | 12 Months Ended
--- | ---
Sep. 30, 2021
STOCK-BASED COMPENSATION |
STOCK-BASED COMPENSATION | 15. STOCK-BASED COMPENSATION On January 2, 2019 the Company granted its employees options to purchase 36,000 ordinary shares at the price of US$5.19 (“Tranche 20”), on January 2, 2020 the Company granted its employees options to purchase 38,000 ordinary shares at the price of US$5.3 (“Tranche 21”), on April 14, 2021 the Company granted its employees options to purchase 160,000 ordinary shares at the price of US$13.99 (“Tranche 21”). All the options have an expiration date that is 5 to 10 years from the date of grant and vest immediately or over a period of 1 to 5 years. 33,000 and 33,000 options under the 2009 Plan, and 247,300 and 284,370 options under the 2014 Plan were outstanding as of September 30, 2020 and 2021 respectively. All the option awards have an exercise price of US$5.19 to US$20.7 and expire 5 to 10 years from the date of grant and vest immediately or over a period of 1 to 10 years. For the options outstanding at September 30, 2020 and 2021, the weighted average remaining contractual lives are 0.26 and–nil- years, respectively. The Company recorded share-based compensation expense for share options of RMB904 , RMB658 and RMB 10,952 for the years ended September 30, 2019, 2020 and 2021 respectively. As of September 30, 2020 and 2021, there were RMB-nil- and RMB-nil-of total unrecognized compensation expense related to non-vested share-based compensation arrangement under the 2014 Plan. Under the term of the 2014 Plan, on March 1, 2018, June 1, 2018 and September 1, 2018 the Company granted total of 22,500 restricted shares to its management at an aggregate value of US$167,925, based on the stock closing price of US$8.6, US$7.2 and US$6.6 at March 1, 2018, June 1, 2018 and September 1, 2018, respectively. The vesting period of these shares was 1 year from the grant date, which is March 1, 2019, June 1, 2019 and September 1, 2019, respectively. The Company issued a total of 320,000 restricted shares to its management and employees during the year ended September 30, 2020. The Company recorded share-based compensation expense for restricted shares of RMB11,218, RMB11,566 and RMB -nil- for the years ended September 30, 2019, 2020 and 2021, respectively. During the fiscal year ended September 30, 2020, we awarded an aggregate of 30,000 treasury stock shares to its employees and recorded share-based compensation expense of RMB1,595, and resulted in decrease RMB7,212 cost of treasury stocks. During the fiscal year ended September 30, 2021, we awarded an aggregate of 14,386 treasury stock shares to its employees, and resulted in decrease RMB4,223 cost of treasury stocks. A summary of the stock option activity under the 2005, 2009 and 2014 Plans is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche | ​ | Tranche
​ | ​ | 9 | ​ | 10 | ​ | 11 | ​ | 12 | ​ | 13 | ​ | 14 | ​ | 15 | ​ | 16 | ​ | 17 | ​ | 18 | ​ | 19 | ​ | 20 |  | 21 | ​ | 22
​ | ​ | January 2, | ​ | January 2, | ​ | January 4, | ​ | April 19, | ​ | May 16, | ​ | August 3, | ​ | January 3, | ​ | October 2, | ​ | December 22, | ​ | January 2, | ​ | March 1, | ​ | January 2, | ​ | January 2, | ​ | April 14,
Grant date | ​ | 2014 | ​ | 2015 | ​ | 2016 | ​ | 2016 | ​ | 2016 | ​ | 2016 | ​ | 2017 | ​ | 2017 | ​ | 2017 | ​ | 2018 | ​ | 2018 | ​ | 2019 |  | 2020 | ​ | 2021
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | ​
Outstanding as of September 30, 2019 |  | 34,500 |  | 19,500 |  | 13,500 |  | 60,000 |  | 20,000 |  | 20,000 |  | 18,000 |  | 2,500 |  | 8,800 | ​ | 29,000 | ​ | 20,000 | ​ | 36,000 | ​ | 38,000 | ​ | —
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | -
Number of options granted | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | —
Options exercised | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | —
Options cancelled/expired | ​ | (34,500) | ​ | (19,500) | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | —
Outstanding as of September 30, 2020 | ​ | — | ​ | — | ​ | 13,500 | ​ | 60,000 | ​ | 20,000 | ​ | 20,000 | ​ | 18,000 | ​ | 2,500 | ​ | 8,800 | ​ | 29,000 | ​ | 20,000 | ​ | 36,000 | ​ | 38,000 | ​ | —
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Number of options granted |  | — |  | — |  | — |  | — |  | — |  | — |  | — |  | — |  | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | 160,000
Options exercised |  | — |  | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (1,000) | ​ | — | ​ | — | ​ | — | ​ | — | ​ | (20,930)
Options cancelled/expired | ​ | — | ​ | — | ​ | — | ​ | (60,000) | ​ | (20,000) | ​ | (20,000) | ​ | — | ​ | (2,500) | ​ | (6,000) | ​ | (10,000) | ​ | — | ​ | — | ​ | — | ​ | —
Outstanding as of September 30, 2021 |  | — |  | — |  | 13,500 |  | — |  | — |  | — |  | 18,000 |  | — |  | 1,800 | ​ | 19,000 | ​ | — | ​ | — | ​ | — | ​ | 139,070
Options vested and exercisable | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
At September 30, 2020 | ​ | — | ​ | — | ​ | 13,500 | ​ | 60,000 | ​ | 20,000 | ​ | 20,000 | ​ | 18,000 | ​ | 2,500 | ​ | 8,800 | ​ | 29,000 | ​ | 20,000 | ​ | 36,000 | ​ | 38,000 | ​ | —
At September 30, 2021 | ​ | — | ​ | — | ​ | 13,500 | ​ | — | ​ | — | ​ | — | ​ | 18,000 | ​ | — | ​ | 1,800 | ​ | 19,000 | ​ | — | ​ | — | ​ | — | ​ | 139,070
Weighted average fair value at the grant date (US$) |  | 6.5 |  | 7.5 |  | 9.0 |  | 15.4 |  | 12.4 |  | 14.4 |  | 4.0 |  | 7.7 |  | 4.4 | ​ | 5.1 | ​ | 5.1 | ​ | 4.0 | ​ | 2.5 | ​ | 12.5
​ The fair value of each option granted is estimated on the date of grant using the Black-Scholes Option Pricing Model: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Tranche |  |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche |  | Tranche | ​
​ | ​ | 9 | ​ | ​ | 10 | ​ | 11 | ​ | 12 | ​ | 13 | ​ | 14 | ​ | 15 | ​ | 16 | ​ | 17 | ​ | 18 | ​ | 19 |  | 20 |  | 21 |  | 22 | ​
Exercise price (US$) | ​ | 12.7 | ​ | ​ | 14.8 | ​ | 13.8 | ​ | 20.5 | ​ | 16.5 | ​ | 20 | ​ | 20.7 | ​ | 16.5 | ​ | 8 | ​ | 9.1 | ​ | 8.2 |  | 5.19 | ​ | 5.3 |  | 15.85 | ​
Average risk-free interest rate | ​ | 0.76 | % | ​ | 1.07 | % | 1.73 | % | 1.79 | % | 1.75 | % | 1.55 | % | 1.94 | % | 1.94 | % | 2.26 | % | 2.25 | % | 2.58 | % | 2.49 | % | 1.67 | % | 0.87 | %
Expected option life (year) | ​ | 3 | ​ | ​ | 3 | ​ | 5 | ​ | 10 | ​ | 10 | ​ | 10 | ​ | 5 | ​ | 5 | ​ | 5 | ​ | 5 | ​ | 5 |  | 5 |  | 5 |  | 5 | ​
Volatility rate | ​ | 79.2 | % | ​ | 79.67 | % | 80.72 | % | 69.27 | % | 69.92 | % | 65.37 | % | 63.87 | % | 52.40 | % | 63.20 | % | 64.60 | % | 68.20 | % | 103 | % | 52.60 | % | 109.90 | %
Dividend yield | ​ | — | ​ | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — | ​ | — |  | — |  | — |  | — | ​
​ The aggregate intrinsic value as of September 30, 2021 and 2020 is US$219 and US$344, respectively.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration